Nf Kappa B Essential Modulator

Introduction

The NF-κB essential modulator (NEMO), also known by its gene symbol IKBKG or as IKKγ (inhibitor of NF-κB kinase gamma), is a critical regulatory subunit of the IκB kinase (IKK) complex. This complex serves as a central hub in the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, a fundamental biological system that governs a vast array of cellular processes.

Biological Basis

The NF-κB signaling pathway is a ubiquitous and essential pathway in eukaryotes, playing a pivotal role in immune responses, inflammation, cell survival, proliferation, and differentiation. NEMO is indispensable for the proper activation of the IKK complex, which consists of two catalytic subunits, IKKα and IKKβ, and the regulatory subunit NEMO. Upon stimulation by diverse extracellular and intracellular signals—such as cytokines (e.g., TNFα, IL-1), pathogen-associated molecular patterns (PAMPs), or stress stimuli—NEMOacts as a scaffold, recruiting upstream signaling molecules and facilitating the activation of IKKα and IKKβ. The activated IKK complex then phosphorylates specific serine residues on IκB inhibitory proteins, marking them for ubiquitination and subsequent degradation by the proteasome. The degradation of IκB proteins releases theNF-κB transcription factors, allowing them to translocate into the nucleus. Once in the nucleus, NF-κB binds to specific DNA sequences in the promoters of target genes, thereby activating or repressing their expression, which in turn orchestrates cellular responses related to immunity, inflammation, and cell fate.

Clinical Relevance

Dysregulation of NEMO and the NF-κB pathway is implicated in the pathogenesis of a wide spectrum of human diseases. Inherited mutations in the IKBKG gene, encoding NEMO, can lead to rare but severe primary immunodeficiency disorders, most notably X-linked anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID). This condition is characterized by developmental defects affecting ectodermal structures (including skin, hair, teeth, and sweat glands) and profound immunodeficiency, resulting in increased susceptibility to recurrent bacterial, viral, and fungal infections.

Beyond rare genetic conditions, aberrant and chronic activation of the NF-κB pathway, often involving NEMO, contributes significantly to the development and progression of numerous common diseases. These include chronic inflammatory and autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Furthermore, constitutive activation ofNF-κB is a hallmark of many cancers, where it promotes tumor cell proliferation, survival, metastasis, angiogenesis, and resistance to conventional therapies. Consequently, NEMO and other components of the NF-κB pathway are actively investigated as promising therapeutic targets for drug development in these debilitating conditions.

Social Importance

Understanding the multifaceted roles of NEMO in both physiological and pathological contexts holds significant social importance. Research into NEMOprovides fundamental insights into the intricate mechanisms that govern immune regulation and inflammation, which are crucial for maintaining health and combating disease. For individuals affected by rare genetic disorders like EDA-ID, this research offers hope for improved diagnostic tools, better disease management strategies, and the potential for novel gene-based or targeted therapies. In the broader public health context, the insights gained from studyingNEMOcontribute to the development of new treatments for widespread conditions such as cancer and chronic inflammatory diseases. By identifying specific molecular targets within theNF-κBpathway, scientists aim to create more effective and less toxic therapeutic interventions, thereby improving the quality of life and health outcomes for millions worldwide. This understanding also supports the advancement of personalized medicine, allowing for tailored treatments based on an individual’s specific genetic variations and disease characteristics.

Limitations

Methodological and Statistical Considerations

The interpretation of genetic associations is subject to several methodological and statistical constraints inherent in genome-wide association studies (GWAS). Many studies, despite their scope, may have limited power to robustly detect genetic associations with small effect sizes, or to fully explore complex interactions between genetic variants and other factors. ^[1]This limitation suggests that some true genetic associations with modest effects might remain undiscovered, and conversely, observed effect sizes for detected variants could be subject to inflation, a phenomenon common in initial discovery phases. Furthermore, the reliance on genotyping platforms that assay only a subset of all known single nucleotide polymorphisms (SNPs) can lead to incomplete coverage of the genome, potentially missing relevant genetic variants or hindering a comprehensive understanding of specific genomic regions.^[2]

Validating genetic findings typically requires replication in independent populations, a process that studies frequently acknowledge as essential for confirming true positive associations. ^[3] Discrepancies in replication outcomes can stem from differences in statistical power, variations in study design (e.g., cohort versus case-control studies), or how phenotypes are precisely defined and adjusted for covariates. ^[1] For instance, non-replication at the individual SNP level might occur if different studies identify distinct but strongly linked SNPs to an underlying causal variant, or if multiple causal variants exist within the same gene region. ^[1] Additionally, analyses that pool sexes may overlook sex-specific genetic effects on certain phenotypes, potentially missing important associations that manifest differently between males and females. ^[2]

Population Specificity and Generalizability

A significant limitation in many genetic studies is the focus on populations of predominantly European ancestry, which can restrict the generalizability of findings to other ancestral groups. ^[4] While meticulous efforts are often made to control for population stratification within these groups through methods like genomic control or principal component analysis, the exclusion of individuals who do not cluster with the main study population means that the genetic architecture for other ancestral backgrounds remains largely unexplored. ^[4]Studies conducted in founder populations, such as the North Finland Birth Cohort (NFBC1966), offer valuable insights due to reduced genetic heterogeneity. However, the unique genetic makeup of such isolates may not fully reflect the genetic landscape of more outbred, diverse populations, potentially limiting the direct applicability of their findings to global populations, even if common variants identified might have comparable effect sizes across different European groups.^[1]

Phenotypic Complexity and Unaccounted Factors

The accurate measurement and appropriate statistical adjustment of complex biological traits present considerable challenges in genetic research. Phenotypes are frequently transformed (e.g., natural log-transformed) and adjusted for numerous covariates, including age, sex, body mass index, and medication use, to isolate genetic effects.^[1] For certain biomarkers, values falling below assay detection limits necessitate the use of specialized statistical models, such as Tobit models, which introduce specific assumptions into the analysis. ^[3] When phenotypes are derived from averaged observations, such as repeated measures within an individual or data from monozygotic twins, careful scaling is required to accurately estimate effect sizes and the proportion of variance explained in the wider population, adding layers of complexity to the interpretation of genetic contributions. ^[5]

Genetic associations are often influenced by a complex interplay of environmental factors and gene-environment interactions, which are challenging to fully capture and model within current study designs. Present genome-wide association studies (GWAS) are primarily designed to detect common genetic variants and may not adequately account for the cumulative contribution of rare variants, which could collectively explain a substantial portion of trait variance. ^[1]Furthermore, the intricate relationship between genetic predispositions and environmental variables, such as lifestyle factors or early-life exposures, represents a significant knowledge gap. While some studies attempt to explore these interactions, power limitations often render such analyses exploratory, underscoring the remaining “missing heritability” that cannot be fully explained by currently identified common variants or simple genetic models.^[1]

Variants

Genetic variations can influence a wide array of biological processes, from cellular signaling to metabolic regulation and protein trafficking, often with implications for immune responses and inflammatory pathways, such as those governed by NF-kappa B essential modulator (NEMO). The variantrs1354034 in the ARHGEF3 gene and rs190361203 in the STK3 gene are examples of how changes in genes involved in cell signaling can have broader physiological effects. ARHGEF3encodes a Rho guanine nucleotide exchange factor, a protein that activates Rho GTPases, which are key regulators of the cytoskeleton, cell migration, and adhesion.^[6] Alterations in Rho GTPase signaling, potentially influenced by rs1354034 , can modulate the activation of transcription factors like NF-κB, which plays a central role in immune and inflammatory responses, including those mediated by NEMO. Similarly, STK3(Serine/Threonine Kinase 3) is a core component of the Hippo signaling pathway, a critical regulator of organ size, cell proliferation, and apoptosis.^[7] The rs190361203 variant may affect the activity of STK3, thereby influencing cellular growth control and potentially interacting with stress response pathways that converge on NF-κB signaling, given the extensive crosstalk between cellular homeostasis and inflammatory cascades.

The SLC22A5 gene, featuring the rs274555 variant, plays a crucial role in cellular metabolism by encoding the organic cation/carnitine transporter 2 (OCTN2). This transporter is primarily responsible for the uptake of carnitine into cells, a process essential for the transport of long-chain fatty acids into mitochondria for energy production.^[8] Variations like rs274555 could affect carnitine transport efficiency, thereby impacting cellular energy metabolism and potentially leading to metabolic stress. Such metabolic disruptions can trigger cellular defense mechanisms and inflammatory responses, which are often orchestrated by the NF-κB pathway, with NEMO being an essential component for its activation.^[9] Therefore, a variant in SLC22A5 could indirectly influence the inflammatory state and the activity of the NEMO-dependent NF-κB cascade through its metabolic consequences.

Other variants, such as rs143024324 in the VPS13B gene and rs188285518 in the VPS36 gene, are associated with processes related to protein sorting and membrane trafficking. VPS13B is involved in the formation of lipid transfer proteins at membrane contact sites, which are critical for intracellular transport and organelle communication. ^[10] The rs143024324 variant might alter this intricate trafficking, potentially affecting the proper localization or degradation of immune receptors and signaling molecules. Similarly, VPS36 is a component of the ESCRT-II complex, which is vital for sorting ubiquitinated membrane proteins into multivesicular bodies for lysosomal degradation . The rs188285518 variant could impact this degradation pathway, leading to altered cell surface receptor expression or accumulation of misfolded proteins. Both VPS13B and VPS36 variations can thus indirectly influence immune cell function and inflammatory signaling, as the proper regulation of cell surface receptors and intracellular signaling hubs is crucial for the precise activation and control of the NF-κB essential modulator and the NF-κB pathway in response to various stimuli.

Key Variants

RS ID	Gene	Related Traits
rs1354034	ARHGEF3	platelet count platelet crit reticulocyte count platelet volume lymphocyte count
rs274555	SLC22A5	lean body mass lymphocyte count level of tudor and KH domain-containing protein in blood alpha-taxilin measurement amount of arylsulfatase B (human) in blood
rs190361203	STK3	NF-kappa-B essential modulator measurement
rs143024324	VPS13B	NF-kappa-B essential modulator measurement
rs188285518	VPS36	level of 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial in blood NF-kappa-B essential modulator measurement level of STAM-binding protein in blood level of integrin beta-5 in blood

Biological Background for ‘nf kappa b essential modulator’

Molecular Signaling and Cellular Regulation

Cellular functions are tightly controlled by intricate molecular signaling pathways that respond to various internal and external cues. The mitogen-activated protein kinase (MAPK) pathway, for instance, is a fundamental signaling cascade involved in processes such as cell growth, proliferation, differentiation, and stress responses, with its activation observed to be influenced by factors like age and acute exercise in human skeletal muscle.^[11]Another critical pathway involves ErbB receptors, which are activated by members of the epidermal growth factor (EGF) family, including neuregulin-2 (NRG2). This ErbB signaling plays a significant role in angiogenesis, the formation of new blood vessels, and the proliferation of endothelial cells. ^[12]

Furthermore, cyclic nucleotide signaling, involving cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is crucial for diverse cellular activities, particularly in vascular physiology. TheCFTR(cystic fibrosis transmembrane conductance regulator) chloride channel is known to regulate cAMP-dependent chloride transport and vasorelaxation in smooth muscle cells^[13]and is also expressed in endothelial cells where it functions as a cyclic nucleotide-regulated chloride channel.^[14] Phosphodiesterase 5 (PDE5) is an enzyme that hydrolyzes both cGMP and cAMP, thereby modulating their signaling effects, and its isoform PDE5Acan have its expression increased by Angiotensin II, leading to antagonism of cGMP signaling in vascular smooth muscle cells.^[15]

Inflammatory and Immune Pathways

Inflammation is a complex biological response of body tissues to harmful stimuli, and its regulation involves numerous biomolecules and pathways. Carboxypeptidase N, for example, is recognized as a pleiotropic regulator of inflammation, influencing various aspects of the immune response. ^[16]Several key inflammatory markers are routinely assessed to monitor immune status and disease progression, including C-reactive protein (CRP), interleukin-6, monocyte chemoattractant protein-1 (MCP1), myeloperoxidase, CD40 ligand, osteoprotegerin, and P-selectin.^[3]

Genetic variations can significantly impact the regulation of these inflammatory mediators. Polymorphisms within the HNF1Agene, which encodes hepatocyte nuclear factor-1 alpha, have been found to be associated with circulating C-reactive protein levels.^[17]Additionally, specific single nucleotide polymorphisms (SNPs) within theABO gene, such as rs8176746 and rs505922 , are linked to variations in tumor necrosis factor-alpha (TNF-alpha) levels. ^[4] The O blood group polymorphism (rs8176719 ) is characterized by a deletion that results in a premature termination codon, highlighting how genetic changes can influence immune-related protein expression. ^[4]

Vascular and Cardiac System Biology

The proper functioning of the vascular and cardiac systems is essential for overall health, involving coordinated cellular and molecular processes. Endothelial cells and vascular smooth muscle cells play critical roles in regulating blood vessel tone and structure. TheCFTRchloride channel, expressed in both vascular smooth muscle cells and endothelial cells, is crucial for vasorelaxation; its disruption can prevent cAMP-dependent vasorelaxation in experimental settings^[13]. ^[14] Phosphodiesterase 5 (PDE5), widely expressed in the vasculature, degrades cGMP, thereby contributing to the contracted state of blood vessels, and its inhibition is a known therapeutic target. ^[12]

Angiogenesis and endothelial cell proliferation are vital for vascular development and repair, processes in which NRG2 and ErbB receptor signaling are implicated. ^[12] Conversely, certain N-terminal regions of NRG2 isoforms have been shown to possess inhibitory activity on angiogenesis. ^[18] Platelet derived growth factor-C (PDGFC) is highly expressed in vascular smooth muscle cells and renal mesangial cells, and is thought to be involved in platelet biology, further highlighting its role in vascular health.^[2] At the cardiac level, transcription factors like MEF2C are instrumental in controlling cardiac morphogenesis and myogenesis ^[19] though overexpression of factors like MEF2A and MEF2Ccan paradoxically lead to conditions such as dilated cardiomyopathy.^[20]

Genetic Mechanisms and Metabolic Homeostasis

Genetic mechanisms underpin a vast array of physiological processes and metabolic traits, with single nucleotide polymorphisms (SNPs) frequently serving as markers for genetic influence. For example, common SNPs in theHMGCR gene, which encodes HMG-CoA reductase, are associated with alternative splicing of exon 13. ^[21]Alternative splicing is a key regulatory mechanism that allows a single gene to produce multiple protein isoforms, and its disruption is known to be involved in human disease.^[22] The identification of protein quantitative trait loci (pQTLs) further demonstrates that genetic variations can directly influence the plasma levels of specific proteins. ^[4]

Beyond protein levels, genetic factors are crucial for maintaining metabolic homeostasis. The pantothenate kinase gene (PANK1), for instance, is functionally linked to glucose metabolism, with studies showing that its chemical knockout can result in a hypoglycemic phenotype.^[1] Similarly, genes like FTO and MC4Rare established loci influencing body mass index (BMI).^[1]Genetic variants also impact hematological phenotypes and hemostatic factors, with genes such asKLF1 (Kruppel-like factor 1) and ITGB3 (integrin, beta 3) influencing various red blood cell characteristics and platelet aggregation. ^[2]

Pathways and Mechanisms

Intracellular Signaling Cascades and Transcriptional Control

Cellular signaling networks orchestrate diverse physiological responses, involving complex cascades that transmit extracellular stimuli into intracellular actions. For instance, the mitogen-activated protein kinase (MAPK) pathway is a critical signaling cascade, with its activation demonstrated to affect human skeletal muscle in response to factors like age and acute exercise.^[11] This pathway’s intricate regulation involves protein families like human tribbles, which control MAPK cascades, suggesting roles in signal amplification or attenuation through protein modification. ^[23]Beyond general stress responses, specific receptor-mediated pathways, such as those involving angiotensin II, regulate vascular smooth muscle cell function by increasing phosphodiesterase 5A expression, thereby antagonizing cGMP signaling.^[15]Similarly, the thyroid hormone receptor interacts with distinct protein classes, modulating gene expression depending on the presence or absence of thyroid hormone.^[24]

Transcriptional regulation is a key downstream output of many signaling pathways, governing gene expression through the binding of specific transcription factors to DNA. The 5’-AMP-activated protein kinase (AMPK), with its gamma2 subunit (PRKAG2), plays a role in cellular energy sensing and metabolic control, and its genomic organization has been characterized. ^[25] Cardiac morphogenesis and myogenesis are notably controlled by transcription factors like MEF2C, which, when dysregulated, can lead to conditions such as dilated cardiomyopathy.^[19]Furthermore, the human C-reactive protein promoter is synergistically trans-activated by transcription factorHNF-1 binding at two distinct sites, highlighting complex combinatorial control over inflammatory gene expression. ^[26]

Regulation of Metabolic Homeostasis

Metabolic pathways are fundamental to maintaining cellular energy balance and synthesizing essential biomolecules, with their regulation being tightly controlled to adapt to varying physiological demands. Lipid metabolism, for example, is influenced by proteins like ANGPTL3 and ANGPTL4, which regulate triglyceride levels and high-density lipoprotein (HDL).^[27] A central enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), is subject to intricate regulation, including its catalytic activity and degradation rate, which is influenced by its oligomerization state. ^[28] The mevalonate pathway, in which HMGCR is a key component, is also regulated by mechanisms involving SREBP-2, linking isoprenoid and adenosylcobalamin metabolism. ^[29]

Glucose metabolism is another critical area of metabolic regulation, impacting energy production and susceptibility to metabolic diseases. Studies have indicated that pantothenate kinase plays a role in glucose metabolism, with its knockout leading to a hypoglycemic phenotype.^[1] Variants in genes like GCKR(glucokinase regulatory protein) are associated with elevated fasting serum triacylglycerol and reduced insulinaemia, influencing the risk of type 2 diabetes.^[30]Furthermore, the functional analysis of human glucokinase gene mutations reveals regulatory mechanisms underlying its activity, particularly in conditions like maturity-onset diabetes of the young (MODY2).^[31]

Post-Translational Modifications and Gene Expression Dynamics

Beyond transcriptional control, regulatory mechanisms at the post-translational level significantly impact protein function, stability, and cellular localization. Protein modification, such as that mediated by the tribbles family of proteins, is crucial for controlling mitogen-activated protein kinase cascades, often influencing the stability or activity of signaling components. ^[23] These modifications allow for rapid and reversible changes in protein function, providing fine-tuned control over cellular processes without altering gene expression levels.

Gene expression dynamics are also profoundly influenced by alternative splicing, a process that allows a single gene to encode multiple protein isoforms with potentially distinct functions. This mechanism is a key determinant of protein diversity and is involved in numerous biological processes and human diseases. ^[32]For instance, common single nucleotide polymorphisms (SNPs) in HMGCR have been shown to affect the alternative splicing of exon 13, influencing LDL-cholesterol levels. ^[21] Similarly, alternative splicing of APOBmRNA can generate a novel isoform of apolipoprotein B, highlighting its role in diversifying protein output from a single gene.^[33]

Systemic Integration and Disease Pathogenesis

Biological systems operate through the intricate integration of multiple pathways, where crosstalk and network interactions give rise to emergent properties and physiological responses. Inflammation, a complex systemic response, is regulated by proteins such as carboxypeptidase N (CPN), which acts as a pleiotropic regulator. ^[16] Mediators like TNF-alpha and IL-6 are subject to biological variations and genetic polymorphisms, underscoring the genetic component of inflammatory responses. ^[34] Pathway crosstalk is evident in the interaction between variants in the PPARG and IL-6genes, influencing obesity-related metabolic risk factors.^[35]

Dysregulation within these integrated networks can lead to various disease states, highlighting critical disease-relevant mechanisms and potential therapeutic targets. Type 2 diabetes, for example, is associated with novel risk loci identified through genome-wide association studies, involving genes likeGCKR and KCNJ11(Kir6.2), which influence glucose and insulin metabolism.^[36]Cardiovascular diseases such as coronary artery disease are linked to specific genetic loci influencing lipid concentrations, including those associated withLDL-cholesterol, HDL-cholesterol, or triglycerides. ^[37]Furthermore, conditions like nonalcoholic fatty liver disease involve specific mechanisms such as glycosylphosphatidylinositol-specific phospholipase D activity.^[38]

References

[1] Sabatti, C. et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet 40 (2008): 1345-1352.

[2] Yang, Q., et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, 2007.

[3] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, 2007.

[4] Melzer, D., et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, 2008.

[5] Benyamin, B., et al. “Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels.”Am J Hum Genet, 2009.

[6] Hall, Alan. “Rho GTPases and the actin cytoskeleton.” Science, vol. 279, no. 5350, 1998, pp. 509-514.

[7] Yu, Fuxing-Li, et al. “The Hippo pathway: a master regulator of organ size, cell proliferation, and cancer.”Cell, vol. 163, no. 4, 2015, pp. 811-828.

[8] Rebouche, Charles J. “Carnitine function and requirements during the life cycle.”Annual Review of Nutrition, vol. 24, 2004, pp. 175-202.

[9] Pahl, H. L. “Activators and targets of the NF-kappaB transcription factor.” Oncogene, vol. 18, no. 49, 1999, pp. 6853-6866.

[10] Schekman, Randy, and James E. Rothman. “The Golgi apparatus and the secretory pathway.” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 12, 2014, pp. a016202.

[11] Williamson, D. et al. “Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle.”J Physiol 547 (2003): 977-987.

[12] Vasan, R. S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, 2007.

[13] Robert, R., et al. “Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl-transport of mouse aortic smooth muscle cells.”Journal of Physiology (London), vol. 568, no. 2, 2005, pp. 483-495.

[14] Tousson, A. et al. “Characterization of CFTR expression and chloride channel activity in human endothelia.” Am J Physiol Cell Physiol 275 (1999): C1555-C1564.

[15] Kim, D. et al. “Angiotensin II increases phosphodiesterase 5A expression in vas-cular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.”J Mol Cell Cardiol 38 (2005): 175-184.

[16] Matthews, K.W., et al. “Carboxypeptidase N: A pleiotropic regulator of inflammation.” Molecular Immunology, vol. 40, no. 14-15, 2004, pp. 785-793.

[17] Reiner, Alexander P., et al. “Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein.”American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1193-1201.

[18] Nakano, N., et al. “The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis.” Journal of Biological Chemistry, vol. 279, no. 12, 2004, pp. 11465-11470.

[19] Lin, Q. et al. “Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C.” Science 276 (1997): 1404-1407.

[20] Xu, J. et al. “Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice.”J Biol Chem 281 (2006): 9152-9162.

[21] Burkhardt, R. et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol (2008).

[22] Caceres, J.F. and Kornblihtt, A.R. “Alternative splicing: multiple control mechanisms and involvement in human disease.”Trends Genet 18 (2002): 186-193.

[23] Kiss-Toth, E. et al. “Human tribbles, a protein family controlling mitogen-activated protein kinase cascades.” J Biol Chem 279 (2004): 42703–42708.

[24] Lee, J.W. et al. “Two classes of proteins dependent on either the pres-ence or absence of thyroid hormone for interaction with the thyroid hormone receptor.”Mol. Endocrinol. 9 (1995): 243–254.

[25] Lang, T. et al. “Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma2 subunit of 5’-AMP-activated pro-tein kinase, to human chromosome 7q36.” Genomics 70 (2000): 258-263.

[26] Toniatti, C. et al. “Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.”EMBO J. 9 (1990): 4467–4475.

[27] Koishi, R. et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet 30 (2002): 151–157.

[28] Istvan, E.S. et al. “Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.” Embo J 19 (2000): 819–830.

[29] Goldstein, J.L. and Brown, M.S. “Regulation of the mevalonate pathway.” Nature 343 (1990): 425–430.

[30] Ridker, P.M. et al. “Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”Am J Hum Genet 82 (2008): 1185–1198.

[31] Garcia-Herrero, C.M. et al. “Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mecha-nisms of glucokinase activity.”Diabetologia 50 (2007): 325-333.

[32] Matlin, A.J. et al. “Understanding alternative splicing: towards a cellular code.” Nat Rev Mol Cell Biol 6 (2005): 386–398.

[33] Khoo, B. et al. “Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.” BMC Mol Biol 8 (2007): 3.

[34] Haddy, N. et al. “Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort.” Eur J Hum Genet 13 (2005): 109-117.

[35] Barbieri, M. et al. “Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors.”Exp Gerontol 40 (2005): 599-604.

[36] Sladek, R. et al. “A genome-wide associ-ation study identifies novel risk loci for type 2 diabetes.” Nature 445 (2007): 881-885.

[37] Samani, N.J. et al. “Genomewide association analysis of coronary artery disease.”N Engl J Med 357 (2007): 443–453.

[38] Chalasani, N. et al. “Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: A preliminary study.”J. Clin. Endocrinol. Metab. 91 (2006): 2279–2285.